| Identification | Back Directory | [Name]
UC-514321 | [CAS]
299420-83-0 | [Synonyms]
UC-514321
1,3-Benzodioxol-5-ol, 6-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-morpholinylmethyl]- | [Molecular Formula]
C26H35NO5 | [MDL Number]
MFCD00667297 | [MOL File]
299420-83-0.mol | [Molecular Weight]
441.56 |
| Chemical Properties | Back Directory | [Boiling point ]
514.5±50.0 °C(Predicted) | [density ]
1.186±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.80±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity[1]. | [in vivo]
UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models[1]. | Animal Model: | MLL-AF9-AML mice and AE9a-AML model[1]. | | Dosage: | 2.5 mg/kg. | | Administration: | IP., once per day, for 10 days. | | Result: | Showed an improved therapeutic effect in AML mouse models in vivo.
Prolonged the median survival over three fold.
|
| [IC 50]
STAT3; STAT5; TET1 | [References]
[1] Jiang X, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017 Dec 13;8(1):2099. DOI:10.1038/s41467-017-02290-w |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|